Skip to main content
. Author manuscript; available in PMC: 2015 Jul 3.
Published in final edited form as: Cell. 2014 Jun 19;158(1):185–197. doi: 10.1016/j.cell.2014.06.003

Figure 1. Spontaneous pancreatic tumor relapse after complete regression upon KrasG12D inactivation.

Figure 1

(A) Representative MRI scan shows initial tumor regression (3 weeks) but subsequent relapse (14 weeks) after doxy withdrawal. (B) Kaplan-Meier overall survival analysis for iKras; p53L/+ mice after doxy withdrawal. On: mice were fed with doxy. Off: Mice with advanced PDAC were switched to doxy-free water 8-15 weeks after on doxy and observed for relapse. (C) Histopathological characterization of the relapse tumors showing poorly differentiated (i) or sarcomatoid (ii) relapse tumors, with liver (iii) and lung (iv) metastasis (denoted by arrow). (D) Quantitative comparison of histopathological features between primary and relapse tumors. (E) qRT-PCR for KrasG12D transgene shows expression in relapse tumors. Data represented as relative normalized expression. (F) Measurement of Ras activity in relapse tumors. For E and F; Two independent iKras cells were maintained in the presence (+) or absence (-) of doxy for 24 hr and used as controls. Error bars represent SD of duplicate samples. (G) The relapse tumors were stained with antibodies against pErk.

See also Figure S1.